News

In April 2013, GSK hired Humphrey’s Chinese corporate investigations business, ChinaWhys, to investigate who is behind a suspected smear campaign against the company. In July 2013, Humphrey and

Teva submitted this CP according to the FDA’s procedural guidance and in accordance with the Agency’s desire to facilitate public review and comment regarding new scientific data on

NAI had been named as a co-defendant in cases involving a dietary supplement called Jack3d, which contains 1,3-dimethylylamylamine (also known as DMAA), which was formulated, made for and

"LPC has been an important partner over the years and we are pleased to continue our relationship with them. This facility gives us an additional option in funding

Medicure also received an option to acquire all of the remaining issued shares of Apicore LLC and the holding company of Apicore US LLC, within the next 3

The approval follows a priority review of the Beleodaq new drug application (NDA) and was an Early Approval action prior to the 09 August 2014 PDUFA (Prescription Drug

The recently signed Memoranda of Understanding with researchers from Ryerson University and the University of Ottawa will contribute towards building a better knowledge base surrounding medical marijuana in

As part of the agreement, Seragon will receive an upfront cash payment of $725m from Genentech and additional contingent payments of up to $1bn based on achievement of

The company said that the currently marketed bendamustine HCI product is a lyophilized powder that requires reconstitution and dilution in 500mL of saline or a sodium chloride /